Abbott has trailed medtech competitors in bringing a PFA device to market, but now plans to accelerate its European rollout in the second half of this year, after beginning with EU physicians familiar with the system from the company’s clinical trials.

Boston Scientific reported surging electrophysiology sales in 2024, fueled by the success of its Farapulse PFA device, and Medtronic projected strong growth in its cardiac ablation solutions business. J&J, meanwhile, suffered a setback when it paused the rollout of its Varipulse PFA device due to reports of neurovascular events. J&J has since resumed cases after determining the devices worked as intended.

Abbott’s share of the electrophysiology market has dipped as its rivals introduced their PFA systems over the past year, said Citi Research analyst Joanne Wuensch. But the company should be able to shore up its market share with the Volt launch, Wuensch said in a Thursday note to clients.